文献速递血栓与止血淋巴瘤

艾曲泊帕治疗继发于慢性淋巴增殖性疾病的免疫性血小板减少症:2期多中心研究

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
PubMed 文献 · Blood · 2019-01-01

这项多中心2期前瞻性24周研究纳入18例继发于慢性淋巴增殖性疾病(LPD)的免疫性血小板减少症(ITP)患者,评估艾曲泊帕的安全性与疗效。第4周缓解率为78%(95%CI 58%-97%),完全缓解(CR)率50%(95%CI 43%-57%);第24周缓解率59%(95%CI 36%-82%),CR率30%(95%CI 8%-52%)。未报告>2级不良事件,提示艾曲泊帕在该人群中有效且耐受良好。

要点

  • 第4周缓解率78%,CR率50%;第24周缓解率59%,CR率30%。
  • 中位用药暴露16个月,第4周与第24周中位剂量均为50 mg/日。
  • 未报告>2级不良事件,耐受性良好。

核心结论

  • 艾曲泊帕对继发于LPD的ITP具有活性且耐受良好。

研究设计与样本

  • 多中心2期前瞻性24周研究,纳入18例继发于LPD的ITP患者,缓解者进入最长5年的扩展研究。

主要发现

  • 第4周缓解率78%(95%CI 58%-97%),CR率50%(95%CI 43%-57%)。
  • 第24周缓解率59%(95%CI 36%-82%),CR率30%(95%CI 8%-52%)。
  • 中位暴露16个月,第4周中位剂量50 mg/日(范围25-100 mg/日),第24周50 mg/日(范围25-150 mg/日)。
  • 未报告>2级不良事件。

关键数值与推荐

  • 入组要求:不需要细胞毒治疗,且血小板计数<30×10^9/L或有出血症状。
  • 艾曲泊帕起始50 mg/日,最大150 mg/日。
  • 主要终点为第4周血小板缓解。

临床怎么用

  • 对继发于LPD、不需要细胞毒治疗的ITP患者,可考虑艾曲泊帕治疗并监测4周及24周血小板反应。

局限性

  • 样本量小(18例),为2期单臂研究,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders (LPDs) is poorly responsive to conventional treatments. We conducted a multicenter phase 2 prospective 24-week study in 18 patients with ITP secondary to LPDs to assess the safety and efficacy of eltrombopag. Responsive patients entered an extension study for up to 5 years. For inclusion, patients should not require cytotoxic treatment and should have a platelet count <30 × 109/L or have symptoms of bleeding. Eltrombopag was initiated at 50 mg/day, with a maximum of 150 mg/day. The primary end point was platelet response after 4 weeks. Median age was 70 years (range, 43-83 years), and 14 patients had chronic lymphocytic leukemia, 2 had classic Hodgkin lymphoma, and 2 had Waldenström macroglobulinemia. All patients had received previous ITP treatments. Response rate at week 4 was 78% (95% confidence interval [CI], 58%-97%), with 50% of patients having a complete response (CR) (95% CI, 43%-57%); respective results at week 24 were 59% (95% CI, 36%-82%) with 30% reaching a CR (95% CI, 8%-52%). Median exposure to eltrombopag was 16 months; median dose at week 4 was 50 mg/day (range, 25-100 mg/day), and at week 24, it was 50 mg/day (range, 25-150 mg/day). No grade >2 adverse events were reported. Eltrombopag is active and well tolerated in ITP secondary to LPDs. This trial was registered at www.clinicaltrials.gov as #NCT01610180.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Visco C, Rodeghiero F, Romano A, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019. PMID: 31570488. doi:10.1182/blood.2019001617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。